• Je něco špatně v tomto záznamu ?

The effect of sodium butyrate and cisplatin on expression of EMT markers

A. Mrkvicova, M. Chmelarova, E. Peterova, R. Havelek, I. Baranova, P. Kazimirova, E. Rudolf, M. Rezacova,

. 2019 ; 14 (1) : e0210889. [pub] 20190117

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045045

Histone modifications play a key role in the epigenetic regulation of gene transcription in cancer cells. Histone acetylations are regulated by two classes of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are increased in ovarian carcinomas and they are involved in carcinogenesis and resistance to chemotherapeutic agents. In our study we investigated anticancer effect of HDAC inhibitor sodium butyrate (NaBu) on cisplatin-sensitive and cisplatin-resistant ovarian cell lines A2780 and A2780cis. A2780 and A2780cis were treated with NaBu alone or in combination with cisplatin (CP). NaBu inhibited the growth of both cell lines and enhanced cytotoxic effect of CP. Exposure to NaBu for 24 h induced cell cycle arrest. The expressions of EMT-related genes and proteins were further investigated by qPCR and western blot analysis. Loss of E-cadherin has been shown to be crucial in ovarian cancer development. We found that NaBu dramatically induce expression of E-cadherin gene (CDH1) and protein levels in A2780 and A2780cis. We investigated correlation between transcription and methylation of CDH1gene. Methylation level analysis in 32 CpG sites in CDH1 gene (promoter/exon1 regions) was performed using bisulfite NGS (Next Generation Sequencing). We found that cisplatin-resistant cell line A2780cis cells differ from their cisplatin-sensitive counterparts in the CDH1 methylation. Methylation in A2780cis cells is elevated compared to A2780. However, NaBu-induced expression of CDH1 was not accompanied by CDH1 demethylation. NaBu treatment induced changes in expression of EMT-related genes and proteins. Interestingly E-cadherin zinc finger transcriptional repressor SNAIL1 was upregulated in both cell lines. Mesenchymal marker vimentin was downregulated. Matrix metalloproteases (MMPs) are necessary for pericellular proteolysis and facilitate migration and invasion of tumour cells. NaBu induced mRNA expression of MMPs, mild changes in activities of gelatinases MMP2 and MMP9 were detected. Our data demonstrate that NaBu sensitizes cisplatin-resistant ovarian cancer cells, re-established E-cadherin expression, but it was not able to reverse the EMT phenotype completely.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045045
003      
CZ-PrNML
005      
20211227134829.0
007      
ta
008      
200109s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0210889 $2 doi
035    __
$a (PubMed)30653577
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mrkvicová, Alena $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. Institute for Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. $7 xx0267751
245    14
$a The effect of sodium butyrate and cisplatin on expression of EMT markers / $c A. Mrkvicova, M. Chmelarova, E. Peterova, R. Havelek, I. Baranova, P. Kazimirova, E. Rudolf, M. Rezacova,
520    9_
$a Histone modifications play a key role in the epigenetic regulation of gene transcription in cancer cells. Histone acetylations are regulated by two classes of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are increased in ovarian carcinomas and they are involved in carcinogenesis and resistance to chemotherapeutic agents. In our study we investigated anticancer effect of HDAC inhibitor sodium butyrate (NaBu) on cisplatin-sensitive and cisplatin-resistant ovarian cell lines A2780 and A2780cis. A2780 and A2780cis were treated with NaBu alone or in combination with cisplatin (CP). NaBu inhibited the growth of both cell lines and enhanced cytotoxic effect of CP. Exposure to NaBu for 24 h induced cell cycle arrest. The expressions of EMT-related genes and proteins were further investigated by qPCR and western blot analysis. Loss of E-cadherin has been shown to be crucial in ovarian cancer development. We found that NaBu dramatically induce expression of E-cadherin gene (CDH1) and protein levels in A2780 and A2780cis. We investigated correlation between transcription and methylation of CDH1gene. Methylation level analysis in 32 CpG sites in CDH1 gene (promoter/exon1 regions) was performed using bisulfite NGS (Next Generation Sequencing). We found that cisplatin-resistant cell line A2780cis cells differ from their cisplatin-sensitive counterparts in the CDH1 methylation. Methylation in A2780cis cells is elevated compared to A2780. However, NaBu-induced expression of CDH1 was not accompanied by CDH1 demethylation. NaBu treatment induced changes in expression of EMT-related genes and proteins. Interestingly E-cadherin zinc finger transcriptional repressor SNAIL1 was upregulated in both cell lines. Mesenchymal marker vimentin was downregulated. Matrix metalloproteases (MMPs) are necessary for pericellular proteolysis and facilitate migration and invasion of tumour cells. NaBu induced mRNA expression of MMPs, mild changes in activities of gelatinases MMP2 and MMP9 were detected. Our data demonstrate that NaBu sensitizes cisplatin-resistant ovarian cancer cells, re-established E-cadherin expression, but it was not able to reverse the EMT phenotype completely.
650    _2
$a CD antigeny $x genetika $7 D015703
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a kyselina máselná $x farmakologie $7 D020148
650    _2
$a kadheriny $x genetika $7 D015820
650    _2
$a buněčný cyklus $x účinky léků $7 D002453
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a cisplatina $x farmakologie $7 D002945
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a epigeneze genetická $x účinky léků $7 D044127
650    _2
$a epitelo-mezenchymální tranzice $x účinky léků $x genetika $7 D058750
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a genetické markery $7 D005819
650    _2
$a histonový kód $x účinky léků $7 D042421
650    _2
$a inhibitory histondeacetylas $x farmakologie $7 D056572
650    _2
$a lidé $7 D006801
650    _2
$a nádory vaječníků $x farmakoterapie $x genetika $x patologie $7 D010051
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chmelarova, Marcela $u Institute for Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Peterova, Eva $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. Second Department of Internal Medicine - Gastroenterology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Havelek, Radim $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Baranová, Ivana $7 xx0247841 $u Institute for Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Kazimirova, Petra $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Rudolf, Emil $u Department of Biology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Rezacova, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 14, č. 1 (2019), s. e0210889
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30653577 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20211227134828 $b ABA008
999    __
$a ok $b bmc $g 1483314 $s 1083718
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 14 $c 1 $d e0210889 $e 20190117 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace